New Insights into Mucosa-Associated Microbiota in Paired Tumor and Non-Tumor Adjacent Mucosal Tissues in Colorectal Cancer Patients DOI Open Access
Adriana González, Asier Fullaondo, David Navarro

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 4008 - 4008

Published: Nov. 29, 2024

Background/Objective: Colorectal cancer (CRC) is one of the most common cancers worldwide. Increasing scientific evidence supports idea that gut microbiota dysbiosis accompanies colorectal tumorigenesis, and these changes could be causative. Implementing analysis in clinical practice limited by sample type, sequencing platform taxonomic classification. This article aims to address limitations, providing new insights into associated with CRC pathogenesis implementing its analyses personalized medicine. Methods: To aim, we evaluate differences bacterial composition 130 paired tumor non-tumor adjacent tissues from a cohort patients Biobank University Navarra, Spain. The V3–V4 region 16S rRNA gene was amplified, sequenced using MinION platform, taxonomically classified NCBI database. Results: our knowledge, this first study report an increased relative abundance Streptococcus periodonticum decreased Corynebacterium CRC. Genera such as Fusobacterium, Leptotrichia showed higher abundances than tissues, previously described literature. Specifically, identified levels Fusobacterium animalis, nucleatum, polymorphum S. tissues. In contrast, genera Bacteroides lower There were also at level between locations. Conclusions: These results, consistent previous studies, further support hypothesis contribute progression, F. nucleatum animalis proposed key pathogenic taxa. Overall, results better understanding CRC-associated microbiota, addressing critical barriers implementation

Language: Английский

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma DOI Open Access
Md. Ataur Rahman,

Meser M. Ali

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975

Published: Aug. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Language: Английский

Citations

9
Evaluating the Impact of Personalized Medicine on Cancer Treatment Outcomes DOI Open Access

Muhammad Yaseen Ujjan,

Asia Noureen,

Dr Lubna Aftab

et al.

Journal of medical & health sciences review., Journal Year: 2025, Volume and Issue: 2(1)

Published: Jan. 15, 2025

Background: Personalized medicine has revolutionized cancer treatment by tailoring therapies to individual genetic and molecular profiles, enabling more targeted effective interventions. Advances in genomic technologies, such as Next-Generation Sequencing (NGS), biomarker analyses have allowed for precise identification of actionable mutations personalized strategies. However, understanding the clinical economic implications these approaches remains a priority optimize their application care. Objective: This study aims evaluate impact on outcomes, focusing progression-free survival (PFS), overall (OS), quality life, cost-effectiveness. By comparing patients receiving treatments with those undergoing standard care, seeks assess benefits challenges associated precision oncology. Methods: A retrospective cohort was conducted at tertiary centers, including diagnosed breast, lung, pancreatic who underwent Genomic profiling performed using NGS (e.g., PD-L1, EGFR, BRCA mutations). Outcomes PFS OS were analyzed Kaplan-Meier analysis Cox proportional hazards models. Cost-effectiveness evaluated through incremental cost-effectiveness ratio (ICER) calculations. Data sources included electronic health records (EHRs), registries, databases The Cancer Genome Atlas (TCGA). Results: Patients interventions demonstrated significantly improved compared (PFS: median 12.4 vs. 8.3 months; OS: 24.6 18.7 months, p < 0.05). Biomarker-driven exhibited highest efficacy, particularly among EGFR BRCA. revealed that medicine, while initially expensive, resulted better quality-adjusted life years (QALYs), making it economically viable long term. Conclusion: findings underscore transformative potential enhancing notable improvements life. high costs accessibility must be addressed ensure broader adoption. Future research should focus scaling exploring utility across diverse populations types.

Language: Английский

Citations

0
MiRNA-155: A double-edged sword in colorectal cancer progression and drug resistance mechanisms DOI Creative Commons
Bashdar Mahmud Hussen, Samia Aziz Sulaiman, Snur Rasool Abdullah

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 299, P. 140134 - 140134

Published: Jan. 20, 2025

Language: Английский

Citations

0
Updates and current states on liposomal vehicles for tumor targeting: precision therapy in the spotlight DOI Creative Commons
Niloufar Rahiman

Cancer Nanotechnology, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 10, 2025

Language: Английский

Citations

0
Recent advances in DNA nanotechnology for cancer detection and therapy: A review DOI

Donya Esmaeilpour,

Matineh Ghomi, Ehsan Nazarzadeh Zare‬

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 142136 - 142136

Published: March 1, 2025

Language: Английский

Citations

0
From Gut to Glory: Unveiling the Microbiome’s Impact on Human Health DOI
Yogesh Raval, M. Guftar Shaikh, Kiran Dudhat

et al.

Regenerative Engineering and Translational Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Language: Английский

Citations

0
The prognostic significance of tumor-specific growth factor in colorectal cancer: an observation study DOI Creative Commons
Yanjun Lu, X. Zhao, Haiyi Liu

et al.

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 21, 2025

The correlation between tumor-specific growth factor (TSGF) and the prognosis of colorectal cancer (CRC)has not been extensively studied. Research was designed to evaluate potential TSGF as a predictive marker for patients with CRC. serum quantified stratified into elevated/normal groups based on established threshold detected using rate method. log-rank test employed survival analysis 3-year overall (OS). Prognostic independence verified through Cox proportional hazards model. receiver operating characteristic (ROC) curves were plotted assess clinical application value TSGF. A total 2223 incorporated in our study. revealed that elevated levels associated poorer multivariate demonstrated an independent prognostic factor. signature covering T staging, N CEA, CA199 superior capability Area Under Curve (AUC) (Delong's p = 0.025). is correlating OS stage I-III CRC patients. Moreover, new including can effectively improve evaluation CRC, thereby contributing precision medication.

Language: Английский

Citations

0
Liquid Biopsy in Cancer Management: Integrating Diagnostics and Clinical Applications DOI Creative Commons

Shashwat Pandey,

Preeti Kumari Yadav

Practical Laboratory Medicine, Journal Year: 2024, Volume and Issue: unknown, P. e00446 - e00446

Published: Dec. 1, 2024

Liquid biopsy is an innovative, minimally invasive diagnostic tool revolutionizing cancer management by enabling the detection and analysis of cancer-related biomarkers from bodily fluids such as blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, which require procedures, liquid offers a more accessible repeatable method for tracking progression, detecting early-stage cancers, monitoring therapeutic responses. The technology primarily focuses on analyzing circulating tumor cells (CTCs), DNA (ctDNA), other cancer-derived genetic materials. These provide critical information heterogeneity, mutation profiles, potential drug resistance. In clinical practice, has demonstrated its utility in identifying actionable mutations, guiding personalized treatment strategies, assessing minimal residual disease (MRD). While holds immense promise, challenges related to sensitivity, specificity, standardization remain. Efforts optimize pre-analytical analytical processes, along with establishment robust regulatory frameworks, are crucial widespread adoption. This abstract highlights transformative diagnosis, prognosis, monitoring, emphasizing role advancing oncology. Further research, trials, harmonization will be vital realizing full precision care.

Language: Английский

Citations

3
LncRNA CCAT2 promotes the proliferation and metastasis of colorectal cancer through activation of the ERK and Wnt signaling pathways by regulating GNB2 expression DOI Creative Commons
Jinhai Tian, Xu Cao,

Zongying Jiang

et al.

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(17)

Published: Sept. 1, 2024

Colorectal cancer (CRC) is a prevalent and lethal tumor, with metastasis being the leading cause of mortality. Previous research has indicated that long non-coding RNA (lncRNA) CCAT2 involved in regulation various tumor progression mechanisms. However, precise role CRC proliferation remains ambiguous. This study seeks to elucidate mechanisms through which influences CRC. High-throughput sequencing RT-qPCR were used detect expression Functional analyses including CCK8, colony formation, wound healing migration, transwell chamber, Muse® Cell Analyzer assays performed effects gene deletion on cells. RNA-pulldown protein mass spectrometry employed identify interaction between GNB2 protein. Increased was found CRC, especially metastatic Deletion inhibited cell proliferation, invasion while promoting apoptosis. The shown modulate alterations affect ERK Wnt signaling pathways, thereby metastasis. plays crucial by modulating pathways its GNB2. These findings highlight importance as key regulatory element underlying

Language: Английский

Citations

1
Global research progress of nanomedicine and colorectal cancer: a bibliometrics and visualization analysis DOI Creative Commons
Siyu Tian, Min Chen

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 6, 2024

Surgery and chemoradiotherapy are the main clinical treatment methods for colorectal cancer (CRC), but prognosis is poor. The emergence of nanomedicine brings bright light to CRC. However, there has not been a comprehensive systematic analysis CRC by bibliometrics.

Language: Английский

Citations

1